Search

Your search keyword '"treprostinil"' showing total 70 results
Start Over Descriptor "treprostinil" Publisher comtex news network, inc.
Sorry, I don't understand your search. ×
70 results on '"treprostinil"'

1. Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA(TM) (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD

Subjects
United States. Food and Drug Administration, United Therapeutics Corp., Actions and defenses, Biotechnology industry, Treprostinil, Drug approval, Pulmonary hypertension -- Care and treatment, Lawsuit/litigation, Banking, finance and accounting industries, Business, Tyvaso (Medication)
Abstract

MORRISVILLE, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it has filed [...]

Published
2024

2. U.S. FDA Grants Tentative Approval of YUTREPIA(TM) (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Subjects
United States. Food and Drug Administration, Lung diseases -- Care and treatment, Treprostinil, Drug approval, Pulmonary hypertension -- Care and treatment, Banking, finance and accounting industries, Business, Tyvaso (Medication)
Abstract

FDA confirmed that the amendment to add PH-ILD to the YUTREPIA NDA was proper and that application otherwise meets the requirements for approval under the Federal Food, Drug, and Cosmetic [...]

Published
2024

4. Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA(TM) (treprostinil) inhalation powder

Subjects
United States. Food and Drug Administration, Treprostinil, Banking, finance and accounting industries, Business, Tyvaso (Medication)
Abstract

On March 28, Judge Andrews removed the injunction issued in the Original Hatch Waxman Litigation On March 29, Judge Bates denied United Therapeutics' motion for temporary restraining order and preliminary [...]

Published
2024

5. Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update

Subjects
United States. Food and Drug Administration, United States. Court of Appeals for the Federal Circuit, Silicon Valley Bank -- Company sales and earnings, United Therapeutics Corp. -- Company sales and earnings, Biotechnology industry -- Company sales and earnings, Banking industry -- Company sales and earnings, Treprostinil, Company earnings/profit, Banking industry, Banking, finance and accounting industries, Business, Tyvaso (Medication)
Abstract

Preparing to launch YUTREPIA(TM) (treprostinil) inhalation powder upon final FDA approval Federal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding '793 Patent invalid Advancing industry leading [...]

Published
2024

7. Liquidia Corporation Provides Update on New Drug Application for YUTREPIA(TM) (treprostinil) inhalation powder

Subjects
United States. Food and Drug Administration, United Therapeutics Corp., Drugs -- Prescribing, Biotechnology industry, Treprostinil, Pulmonary hypertension, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its review [...]

Published
2024

8. Liquidia Corporation Announces Updates to Operations Leadership

Subjects
Business plans, Chief operating officers, Treprostinil, Business planning, Chief financial officers, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, N.C., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today updates and promotions to its operations leadership in advance of the potential [...]

Published
2024

9. Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD

Subjects
United States. Food and Drug Administration, Pipe lines, Lung diseases, Treprostinil, Pulmonary hypertension, Banking, finance and accounting industries, Business, Tyvaso (Medication)
Abstract

Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIA Confirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C., [...]

Published
2024

10. Liquidia Corporation Announces $100 Million in New Financings

Subjects
Private placements (Securities), Treprostinil, Banking, finance and accounting industries, Business
Abstract

Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placement Additional advance of $25.0 million from HealthCare Royalty under current financing [...]

Published
2024

11. MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million

Subjects
Mannkind Corp., United Therapeutics Corp., Biotechnology industry, Treprostinil, Pharmaceutical industry, Banking, finance and accounting industries, Business, Tyvaso (Medication)
Abstract

Sagard Healthcare purchased a 1% royalty in Tyvaso DPI [sup. (R) ] net sales Purchase price of $150 million; additional potential milestone payment of up to $50 million WESTLAKE VILLAGE, [...]

Published
2024

12. Liquidia Announces Pricing of Public Offering of Common Stock

Subjects
Stocks, Treprostinil, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has priced an underwritten public offering of 3,491,620 shares of common stock at a [...]

Published
2023

13. FDA Accepts Submission to Add PH-ILD to YUTREPIA(TM) Label

Subjects
United States. Food and Drug Administration, Respiratory agents, Treprostinil, Pulmonary hypertension -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

Sets PDUFA goal date of January 24, 2024 If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Liquidia [...]

Published
2023

15. U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation

Subjects
Actions and defenses, Treprostinil, Judgments, Lawsuit/litigation, Banking, finance and accounting industries, Business
Abstract

Infringement case now only focused on '793 patent, previously found to be invalid by PTAB in IPR Federal Circuit expected to hear appeal of PTAB decision in late 4th quarter [...]

Published
2023

16. Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America

Subjects
Respiratory agents, Treprostinil, Banking, finance and accounting industries, Business
Abstract

Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizer Liquidia funds $10 million upfront payment from finance agreement [...]

Published
2023

17. Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)

Subjects
United States. Food and Drug Administration, Sandoz Inc., Executives, Treprostinil, Pulmonary hypertension, Pharmaceutical industry, Banking, finance and accounting industries, Business, Remodulin (Medication)
Abstract

Liquidia and Sandoz will collaborate with Mainbridge Health Partners to develop a new infusion pump Liquidia and Sandoz have also extended the term of their promotion agreement for Treprostinil Injection [...]

Published
2022

18. Liquidia Provides Update on Hatch-Waxman Litigation and to Host Call on September 1, 2022, at 8:00am E.T

Subjects
United Therapeutics Corp., Biotechnology industry, Treprostinil, Appellate procedure, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, N.C., Aug 31, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:LQDA), EQNX::TICKER_END -- District Court ruling was favorable on '066 patent and unfavorable on '793 patent -- All patent [...]

Published
2022

20. Liquidia to Participate in Upcoming Investor Conferences

Subjects
St. Regis New York, Treprostinil, Chief financial officers, Hotels and motels -- United States, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, N.C., Aug 01, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:LQDA), EQNX::TICKER_END Liquidia Corporation (NASDAQ: LQDA) announced today that it will be participating at the following investor conferences next [...]

Published
2022

21. Liquidia Announces the Publication of Long-Term Clinical Data from Completed INSPIRE Study in the Journal Pulmonary Circulation

Subjects
Treprostinil, Pulmonary hypertension, Banking, finance and accounting industries, Business, Tyvaso (Medication)
Abstract

MORRISVILLE, N.C., Aug 01, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:LQDA), EQNX::TICKER_END -- Evaluated doses of YUTREPIA(TM) (treprostinil) inhalation powder from 26.5 mcg to 212 mcg which are comparable [...]

Published
2022

22. Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Subjects
Stock options, Treprostinil, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, Jul 25, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:LQDA), EQNX::TICKER_END Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for 2,000 shares of [...]

Published
2022

23. Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Subjects
Stock options, Treprostinil, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, Jul 21, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:LQDA), EQNX::TICKER_END Liquidia Corporation (NASDAQ: LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar, M.D., [...]

Published
2022

24. Liquidia Corporation Added to Russell 2000(R) and 3000(R) Indexes

Subjects
Treprostinil, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, Jun 27, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:LQDA), EQNX::TICKER_END Liquidia Corporation (NASDAQ: LQDA) announced today that the company was added as a member of the US small-cap [...]

Published
2022

25. Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Subjects
Stock options, Treprostinil, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, Jun 24, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:LQDA), EQNX::TICKER_END Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 24,800 [...]

Published
2022

26. Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Subjects
Stock options, Treprostinil, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, Jun 24, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:LQDA), EQNX::TICKER_END Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for 2,000 shares of [...]

Published
2022

27. Liquidia Appoints Rajeev Saggar, M.D., as Chief Medical Officer

Subjects
Treprostinil, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, Jun 20, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:LQDA), EQNX::TICKER_END Liquidia Corporation (NASDAQ: LQDA) ('Liquidia' or the 'Company') today announced the appointment of Rajeev Saggar, M.D., to the [...]

Published
2022

28. Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Subjects
Stock options, Treprostinil, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, Apr 25, 2022 (GLOBE NEWSWIRE via COMTEX) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 35,700 shares of Liquidia's [...]

Published
2022

29. Liquidia Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option

Subjects
United States. Securities and Exchange Commission, Needham and Company Inc., Stocks, Treprostinil, Securities industry, Securities industry, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, Apr 18, 2022 (GLOBE NEWSWIRE via COMTEX) -- Liquidia Corporation (NASDAQ: LQDA) ('Liquidia') today announced the closing of its previously announced underwritten public offering of 11,274,510 shares of its [...]

Published
2022

30. Liquidia Announces Proposed Offering of Common Stock

Subjects
United States. Securities and Exchange Commission, Stocks, Treprostinil, Company securities, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, Apr 12, 2022 (GLOBE NEWSWIRE via COMTEX) -- Liquidia Corporation (NASDAQ: LQDA) ('Liquidia') announced today that it has commenced an underwritten public offering of its common stock. All of [...]

Published
2022

31. Liquidia Announces Pricing of Public Offering of Common Stock

Subjects
United States. Securities and Exchange Commission, Stocks, Treprostinil, Banking, finance and accounting industries, Business
Abstract

MORRISVLLE, Apr 12, 2022 (GLOBE NEWSWIRE via COMTEX) -- Liquidia Corporation (NASDAQ: LQDA) ('Liquidia') announced the pricing of an underwritten public offering of 9,803,922 shares of its common stock at [...]

Published
2022

33. Liquidia Corporation Reports Full-Year 2021 Financial Results and Provides Corporate Update

Subjects
United States. Food and Drug Administration, United Therapeutics Corp., Biotechnology industry, Treprostinil, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, Mar 17, 2022 (GLOBE NEWSWIRE via COMTEX) -- - Received tentative FDA approval of YUTREPIA(TM) (treprostinil) inhalation powder - Expanded use of Treprostinil Injection to include subcutaneous administration - [...]

Published
2022

36. Liquidia Re-Finances Debt Facility With Silicon Valley Bank To Increase To $40.0 Million

Subjects
Silicon Valley Bank -- Finance, Banks (Finance), Banking industry -- Finance, Treprostinil, Syndicated loans, Private banking, Company financing, Banking industry, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, N.C., Jan 07, 2022 (GLOBE NEWSWIRE via COMTEX) -- Liquidia Corporation (NASDAQ: LQDA) announced today the closing of a debt facility on January 7, 2022, with Silicon Valley Bank [...]

Published
2022

37. Liquidia Corporation Announces Chief Executive Officer Transition

Subjects
United Therapeutics Corp. -- Officials and employees, Biotechnology industry -- Officials and employees, Chief executive officers, Treprostinil, Chairpersons, Pulmonary hypertension, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, N.C., Jan 03, 2022 (GLOBE NEWSWIRE via COMTEX) -- Liquidia Corporation (NASDAQ: LQDA) today announced Dr. Roger Jeffs has been appointed as Chief Executive Officer (CEO) effective January 3, [...]

Published
2022

39. FDA Grants Tentative Approval for Liquidia's YUTREPIA(TM) (Treprostinil) Inhalation Powder

Subjects
United States. Food and Drug Administration, Treprostinil, Pulmonary hypertension -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, N.C., Nov 08, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- First dry-powder formulation of treprostinil to meet criteria required for FDA approval -- Final FDA approval may occur in [...]

Published
2021

40. Progress Update on Tyvaso DPI(TM) New Drug Application

Subjects
United States. Food and Drug Administration, Mannkind Corp. -- Buildings and facilities, United Therapeutics Corp. -- Buildings and facilities, Biotechnology industry -- Buildings and facilities, Treprostinil, Pharmaceutical industry -- Buildings and facilities, Banking, finance and accounting industries, Business, Tyvaso (Medication)
Abstract

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Oct 18, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- Complete response received by United Therapeutics cites an open inspection issue at a third-party analytical [...]

Published
2021

42. FDA Completes On-site Pre-Approval Inspection of Liquidia's Morrisville, North Carolina Facility

Subjects
United States. Food and Drug Administration, Treprostinil, Drug approval, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, N.C., Aug 18, 2021 (GLOBE NEWSWIRE via COMTEX) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has completed an on-site Pre-Approval Inspection [...]

Published
2021

43. Corsair Pharma, Inc. to Present at LifeSci Partners Annual Private Company Summer Symposium

Subjects
Conferences and conventions, Treprostinil, Transdermal medication, Pulmonary hypertension, Banking, finance and accounting industries, Business
Abstract

SOUTH SAN FRANCISCO, Jul 15, 2021 (GLOBE NEWSWIRE via COMTEX) -- Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug, today announced it will present at the [...]

Published
2021

44. Corsair Pharma, Inc. to Host Key Opinion Leader Meeting on Pulmonary Arterial Hypertension

Subjects
Treprostinil, Transdermal medication, Pulmonary hypertension, Banking, finance and accounting industries, Business, University of California, Los Angeles. Medical Center
Abstract

SOUTH SAN FRANCISCO, Jun 24, 2021 (GLOBE NEWSWIRE via COMTEX) -- Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug, today announced it will host a Key [...]

Published
2021

45. MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI(TM) With New Drug Application Acceptance From the FDA

Subjects
United States. Food and Drug Administration, Mannkind Corp., United Therapeutics Corp., Biotechnology industry, Treprostinil, Pulmonary hypertension -- Care and treatment, Pharmaceutical industry, Banking, finance and accounting industries, Business, Tyvaso (Medication)
Abstract

DANBURY, Jun 16, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- Tyvaso DPI includes the second compound formulated with MannKind's Technosphere technology to be reviewed by the FDA -- FDA review [...]

Published
2021

46. Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder

Subjects
United States. Food and Drug Administration, Treprostinil, Drug approval, Pulmonary hypertension, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, Jun 02, 2021 (GLOBE NEWSWIRE via COMTEX) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) [...]

Published
2021

47. Liquidia Corporation To Present At The Jefferies Virtual Healthcare Conference

Subjects
Conferences and conventions, Treprostinil, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, May 26, 2021 (GLOBE NEWSWIRE via COMTEX) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an overview and update [...]

Published
2021

48. Liquidia Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension

Subjects
United States. Food and Drug Administration, Treprostinil, Drug approval, Pulmonary hypertension -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

MORRISVILLE, May 10, 2021 (GLOBE NEWSWIRE via COMTEX) -- Liquidia Corporation (NASDAQ: LQDA) announced today that on May 7, 2021, it resubmitted its New Drug Application (NDA) for LIQ861 for [...]

Published
2021

49. Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI(TM) With New Drug Application Submitted to the FDA

Subjects
United States. Food and Drug Administration, Mannkind Corp., United Therapeutics Corp., Biotechnology industry, Treprostinil, Pharmaceutical industry, Banking, finance and accounting industries, Business, Tyvaso (Medication)
Abstract

WESTLAKE VILLAGE, Calif. and DANBURY, Apr 19, 2021 (GLOBE NEWSWIRE via COMTEX) -- MannKind Corporation (Nasdaq: MNKD) and United Therapeutics (Nasdaq: UTHR) reached a milestone today in the development of [...]

Published
2021

50. Liquidia Corporation Announces $21.7 Million Private Placement

Subjects
Morgan Stanley -- Officials and employees, Bupivacaine, Private placements (Securities), Treprostinil, Banking, finance and accounting industries, Business
Abstract

RESEARCH TRIANGLE PARK, Apr 13, 2021 (GLOBE NEWSWIRE via COMTEX) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has entered into a common stock purchase agreement with certain institutional, [...]

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results